About this trial
Accurate intraoperative margin assessment in breast cancer surgery remains challenging. Current reliance on frozen section pathology is limited by prolonged processing time, sampling constraints, and resource intensity, contributing to variable outcomes.
The EndoSCell Scanner is a novel cellular-resolution fluorescence-guided imaging technology designed to address these limitations. It enables real-time, pathology-level visualization of malignant cellular features at the surgical bed. With a 3mm probe allowing comprehensive 360° margin assessment, it reduces procedural time to under five minutes and may significantly lower secondary surgery rates.
This prospective, self-controlled study aims to evaluate the accuracy of the EndoSCell Scanner for intraoperative margin assessment in patients undergoing mastectomy. Its performance will be systematically compared against both frozen section and final paraffin pathology to validate sensitivity and operational efficiency. If proven effective, this technology could become a standard adjunct tool, standardizing precision in breast cancer surgery and improving patient outcomes by enhancing surgical consistency.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 - 70 years
Patients scheduled for breast tumor resection
Clinically or radiologically showing a solitary lesion and
(Before neoadjuvant chemotherapy) Maximum tumor diameter ≤ 5cm;
Disqualifiers
Inflammatory breast cancer;
Patients allergic to methylene blue and sodium fluorescein;
Unable to understand the trial requirements or unable to complete the study follow-up plan;
Pregnant and breastfeeding women;
Trial population
This study will enroll 165 adult female patients scheduled to undergo breast surgery for histologically confirmed breast cancer. Eligible participants must provide written informed consent.
Trial design
Other
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To evaluate the sensitivity and specificity of the EndoSCell Scanner (ES) detection, using paraffin pathology as the gold standard, in comparison to rapid frozen section (FS) pathology.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
West China Hospital
Lead sponsor
Fourth People's Hospital of Sichuan Province
Collaborator
This trial is not recruiting at the moment. You can still explore other options: